[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612169":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":90,"collaborators":92,"id":96,"slug":24,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":24,"eligibilityCriteria":101,"healthyVolunteers":97,"sex":102,"minAge":103,"maxAge":24,"enrollmentInfo":104,"targetDuration":24,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":24,"overallStatus":38,"whyStopped":24,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"H. Lee Moffitt Cancer Center and Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients post-alloHCT","EXPERIMENTAL","Individuals who have previously undergone an allogeneic stem cell transplant (alloHCT).",[13],"Drug: Asciminib",{"label":15,"type":10,"description":16,"interventionNames":17},"Patients post-CAR T cell therapy","Individuals who have received chimeric antigen receptor T cell therapy (CAR T).",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Asciminib","Treatment will be administered on an outpatient basis.",[15,9],null,[26],{"name":27,"affiliation":28,"role":29},"Rawan Faramand, MD","Moffitt Cancer Center","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":24,"email":35},"Valerie Trujillo","CONTACT","813-745-3178","Valerie.Trujillo@moffitt.org",[37],{"facility":28,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Tampa","Florida","33612","United States",{"type":44,"coordinates":45},"Point",[46,47],-82.45843,27.94752,{"lat":47,"lon":46},[50,51,54,56,58,60,62,64,66,68,70,72,74,76,78,80,82,84,86,88],{"name":27,"role":29,"phone":24,"phoneExt":24,"email":24},{"name":52,"role":53,"phone":24,"phoneExt":24,"email":24},"Melissa Alsina, MD","SUB_INVESTIGATOR",{"name":55,"role":53,"phone":24,"phoneExt":24,"email":24},"Nelli Bejanyan, MD",{"name":57,"role":53,"phone":24,"phoneExt":24,"email":24},"Omar Castaneda Puglianini, MD",{"name":59,"role":53,"phone":24,"phoneExt":24,"email":24},"Ciara Freeman, MD",{"name":61,"role":53,"phone":24,"phoneExt":24,"email":24},"Doris Hansen, MD",{"name":63,"role":53,"phone":24,"phoneExt":24,"email":24},"Michael Jain, MD",{"name":65,"role":53,"phone":24,"phoneExt":24,"email":24},"Farhad Khimani, MD",{"name":67,"role":53,"phone":24,"phoneExt":24,"email":24},"Aleksandr Lazaryan, MD",{"name":69,"role":53,"phone":24,"phoneExt":24,"email":24},"Hien Liu, MD",{"name":71,"role":53,"phone":24,"phoneExt":24,"email":24},"Frederick Locke, MD",{"name":73,"role":53,"phone":24,"phoneExt":24,"email":24},"Asmita Mishra, MD",{"name":75,"role":53,"phone":24,"phoneExt":24,"email":24},"Taiga Nishihori, MD",{"name":77,"role":53,"phone":24,"phoneExt":24,"email":24},"Lia Perez, MD",{"name":79,"role":53,"phone":24,"phoneExt":24,"email":24},"Sayeef Mirza, MD",{"name":81,"role":53,"phone":24,"phoneExt":24,"email":24},"Fabiana Perna, MD",{"name":83,"role":53,"phone":24,"phoneExt":24,"email":24},"Joseph Pidala, MD",{"name":85,"role":53,"phone":24,"phoneExt":24,"email":24},"Reshma Ramlal, MD",{"name":87,"role":53,"phone":24,"phoneExt":24,"email":24},"Nancy Torres Luna, MD",{"name":89,"role":53,"phone":24,"phoneExt":24,"email":24},"Bijal Shah, MD",{"type":91,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[93],{"name":94,"class":95},"Novartis","INDUSTRY","100612169",false,"NCT07250087","Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL","Phase 1 Study of Asciminib Maintenance Therapy Following Allogeneic Stem Cell Transplant or Chimeric Antigen Receptor T Cell Therapy (CAR T) to Prevent Relapse in Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of Ph+ B-ALL with detectable Philadelphia chromosome abnormalities\n* Morphologic remission (\\\u003C5% marrow blasts)\n* ECOG performance status 0-2\n* Adequate organ function\n\nExclusion Criteria:\n\n* Active relapsed disease (\\>5% blasts)\n* Grade II-IV acute GVHD requiring systemic steroids\n* Significant organ dysfunction or uncontrolled infection\n* Pregnancy or breastfeeding\n* Prior investigational CAR T product","ALL","18 Years",{"count":105,"type":106},36,"ESTIMATED","INTERVENTIONAL",[109],"PHASE1","The purpose of the study is to see if a study drug called asciminib is safe and okay for people to take after they've had treatment for a type of blood cancer called Philadelphia Chromosome\n\nPositive Acute Lymphoblastic Leukemia (Ph+ B-ALL). We're looking at two groups of adults:\n\none group had an Allogeneic Stem Cell Transplant (alloHCT) cohort A, and the other group had chimeric antigen receptor T cell (CAR T) therapy, cohort B. We also want to figure out what the best dose of asciminib is to use moving forward in future studies.",[112],"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","2026-03-26",{"date":115,"type":116},"2026-03-27","ACTUAL",{"date":118,"type":116},"2026-01-21",{"date":120,"type":106},"2029-11",{"name":5,"class":6},1]